Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Arthritis Rheum. 2005 Oct;52(10):3279-89. doi: 10.1002/art.21306.
Arthritis Rheum. 2005.
PMID: 16200601
Free article.
Clinical Trial.